Phaseline

Companies › CanSino Biologics

CanSino Biologics: clinical trials, targets and expected readouts

8 active drug programs in 13 registered trials: 6 Phase 3, 6 Phase 1, 1 Phase 4; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
Meningococcal polysaccharide conjugate vaccine targeting serogroups A, C, Y, W135 conjugat
–Phase 4Epidemic Meningitis; Meningococcal Meningitis–
PCV13i
13-valent pneumococcal conjugate vaccine
–Phase 3Pneumococcal InfectionsFeb 2027
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine,
Inactivated bacterial toxoids (diphtheria and tetanus) combined with acellular pertussis a
–Phase 3Diphtheria, Tetanus and Acellular Pertussis–
24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid)
Pneumococcal polysaccharide conjugate vaccine with CRM197 and tetanus toxoid carriers targ
–Phase 1Streptococcus Pneumoniae InfectionNov 2026
VLP-Polio low adjuvant dose
Recombinant trivalent poliomyelitis vaccine
–Phase 1PoliomyelitisDec 2026
Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophi
Combined vaccine with acellular pertussis toxoid, diphtheria toxoid, tetanus toxoid, Haemo
–Phase 1Diphtheria, Tetanus and Acellular PertussisFeb 2029
Ad5-105K
Adenovirus serotype 5 vector expressing Mycobacterium tuberculosis antigens
–Phase 1Tuberculosis–
Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Haemophilus influenzae type b polysaccharide conjugate vaccine
HIBPhase 1Haemophilus Influenzae Type B Infection–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06226714ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)Phase 3Meningococcal MeningitisInfectious diseaseSep 2024
NCT05951725Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine,Phase 3Diphtheria, Tetanus and Acellular PertussisInfectious diseaseApr 2025
NCT06857370Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine,Phase 3Diphtheria, Tetanus and Acellular PertussisInfectious diseaseJan 2026
NCT06857370Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine,Phase 3Diphtheria, Tetanus and Acellular PertussisInfectious diseaseJan 2026
NCT06857370Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine,Phase 3Diphtheria, Tetanus and Acellular PertussisInfectious diseaseJan 2026
NCT05935176ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)Phase 4Epidemic MeningitisInfectious diseaseMay 2026
NCT06732583Ad5-105KPhase 1TuberculosisInfectious diseaseAug 2026
NCT06621654Lyophilized Haemophilus Influenzae Type b Conjugate VaccinePhase 1Haemophilus Influenzae Type B InfectionInfectious diseaseOct 2026
NCT0760098324-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid)Phase 1Streptococcus Pneumoniae InfectionInfectious diseaseNov 2026
NCT06577298VLP-Polio low adjuvant dosePhase 1PoliomyelitisInfectious diseaseDec 2026
NCT06577298VLP-Polio low adjuvant dosePhase 1PoliomyelitisInfectious diseaseDec 2026
NCT07017777PCV13iPhase 3Pneumococcal InfectionsInfectious diseaseFeb 2027
NCT07203755Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-HaemophiPhase 1Diphtheria, Tetanus and Acellular PertussisInfectious diseaseFeb 2029

Targets

HIB (1)

Companies with the same targets

–

Companies built like this

Serum Institute of India Anhui Zhifei Longcom Biologic Pharmacy LimmaTech Biologics MAXVAX Biotechnology Limited Liability Company SK Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.